Catherinn and the Ghent University signed a collaboration agreement to explore the SCLC biomarker as potential target for active immunotherapy in Small Cell Lung Cancer.

The group of prof. Karim Vermaelen, CRIG and Tumor Immunology Laboratory, has developed a proprietary platform technology for accelerated production of high yields of activated, antigen loaded autologous dendritic cells. This technology is now used in clinical trial studies for Non-Small Cell Lung Cancer and can potentially also be used for SCLC immunotherapy with the Catherinn proprietary biomarker.

The collaboration consists of two work packages to demonstrate the proof of principle of the immunotherapy in a preclinical setting.